Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium
January 17, 2019 08:00 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the study plan for a Phase 3...
Jounce Therapeutics Reports Third Quarter 2018 Financial Results
November 13, 2018 06:30 ET
|
Jounce Therapeutics, Inc.
- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track - - IND filed and clearance to proceed received for...
Jounce Therapeutics Reports Second Quarter 2018 Financial Results
August 09, 2018 06:30 ET
|
Jounce Therapeutics, Inc.
- Initiated enrollment in dose escalation cohorts of Phase 1/2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab - - Presented preliminary efficacy data...
Navigators Completes Acquisition of Belgian Specialty Insurer
June 07, 2018 04:30 ET
|
The Navigators Group, Inc.
STAMFORD, Conn., June 07, 2018 (GLOBE NEWSWIRE) -- The Navigators Group, Inc. (NASDAQ:NAVG) today announced the completion of the acquisition of Bracht, Deckers & Mackelbert NV (“BDM”), a...
TESARO Summarizes TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting
June 04, 2018 18:00 ET
|
TESARO, Inc.
TOPACIO data for ZEJULA® (niraparib) in combination with an anti-PD-1 mAb highlight promising activity in platinum-resistant/refractory ovarian cancer and triple-negative breast cancer beyond patients...
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
June 04, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts - - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD,...
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
June 02, 2018 16:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
June 02, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the...
NanoString Highlights Record Number of nCounter-Based Abstracts at the 2018 Annual Meeting of the American Society of Clinical Oncology
May 31, 2018 06:00 ET
|
NanoString Technologies, Inc.
More than 50 abstracts highlight the diverse capabilities of NanoString’s technologies in immuno-oncology, biomarker development and validation, and cancer characterization SEATTLE, May 31,...
PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE PV-10 ABSTRACT AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
May 17, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center identifies PV-10 activity, mechanisms of...